MindMed announces its year-end results for 2020, cash-on-hand at US$161 million, including a total cash burn for 2020 of US$24.2 million.
Why Dollar-Cost Averaging Makes Sense For Psychedelic Stocks
Psychedelic stocks have been battered by general market headwinds in recent weeks. Uncertainty could persist. How do investors allocate capital?
Lobe Sciences Added to Horizons Psychedelic Stock Index ETF
Lobe Sciences becomes the latest addition to the Horizons psychedelics ETF (PSYK).
The COVID Conundrum For Psychedelic Stocks
The COVID pandemic is making the need for psychedelic drugs and the commercial potential of the industry much greater. But there is a catch.
Catalent Signs Drug Development Agreement with Cybin Inc for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)
Cybin inks a drug development agreement with Catalent, "the leading global provider" of drug delivery, development and manufacturing solutions.
Traumatic Brain Injury (TBI): Six Psychedelics Companies Target $120 Billion Market
One huge market. Six horses in the race (so far). Lots of prize money to go around.
COMPASS Pathways granted two US patents
Compass is granted two psilocybin formulation patents, for treatment-resistant depression and major depressive disorder.
MindMed Announces Inclusion in FTSE Russell Indexes
MindMed has been added to the FTSE Global Micro-Cap Index and the FTSE Total-Cap Index.
Psychedelic Drugs: The Miracle Drugs of the 21st Century
Are psychedelics "miracle drugs"? If we compare them to the first Miracle Drug, the answer seems to be "yes".
Numinus Announces Closing of $40-Million Bought Deal Financing
Numinus closes on a CAD$40.25 million bought deal financing, upsized from the original CAD$30 million offering.
Red Light Holland Closes Acquisition of SR Wholesale Becoming a Leader in Distribution of Psychedelics
Red Light Holland acquires a Netherlands distributor of psilocybin-based products.
Ty Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM's AI-Driven Psychedelic Digital Therapeutic Technology
MINDCURE adds a new tech specialist to direct the development of its iSTRYM R&D platform.
